Sandoz, a division of Novartis, is at the forefront of improving access to healthcare through the development of biosimilars. These biosimilars are FDA-approved biologics that have undergone rigorous regulatory evaluation to ensure they match the reference medicines in terms of quality, safety, and efficacy. This commitment to high standards not only enhances patient access to essential medications but also addresses critical issues such as drug shortages in the healthcare system. Sandoz's focus on biosimilars exemplifies its dedication to pioneering innovative solutions that meet the needs of patients and healthcare providers alike.

In addition to its work with biosimilars, Sandoz offers a diverse range of products across various therapeutic categories, including anti-infectives, psychotherapeutic drugs, and dermatologicals. The company provides detailed product information, including National Drug Codes (NDCs), dosage forms, and prescribing information, ensuring that healthcare professionals have access to the necessary data for safe and effective treatment. Sandoz's commitment to product safety and corporate responsibility further underscores its mission to enhance patient well-being and foster a more inclusive healthcare environment.

Switzerland

Sandoz is the global leader in generic and biosimilar medicines. ​

​Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance.​

 We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars.

Sandoz (Novartis)

Company Details